Day Fiona, Kumar Mahesh, Fenton Linda, Gedye Craig
*Calvary Mater Newcastle, Waratah †School of Medicine and Public Health, University of Newcastle, Callaghan ‡Hunter Medical Research Institute, School of Biomedical Sciences and Pharmacy, University of Newcastle, New Lambton Heights, NSW, Australia.
J Immunother. 2017 Jan;40(1):36-38. doi: 10.1097/CJI.0000000000000146.
A 72-year-old male patient was receiving second-line chemotherapy for metastatic squamous cell carcinoma of the skin (SCCS) when he was diagnosed with concurrent metastatic melanoma (BRAF mutant). Chemotherapy was ceased and he was treated with 4 cycles of ipilimumab immunotherapy. The patient experienced clinical benefit and durable remission in both malignancies and remains free of cancer progression 8 months after the last cycle of ipilimumab. Response of SCCS to ipilimumab has not been previously described, however this case and recent reports of pembrolizumab efficacy confirm the critical role of the immune system in SCCS pathogenesis and suggest further exploration of checkpoint immunotherapy for the treatment of this disease.
一名72岁男性患者在接受皮肤转移性鳞状细胞癌（SCCS）二线化疗时，被诊断出同时患有转移性黑色素瘤（BRAF突变型）。化疗停止，他接受了4个周期的伊匹木单抗免疫治疗。该患者在两种恶性肿瘤中均获得了临床益处和持久缓解，在最后一个周期的伊匹木单抗治疗8个月后仍无癌症进展。此前尚未描述过SCCS对伊匹木单抗的反应，然而该病例以及近期关于派姆单抗疗效的报道证实了免疫系统在SCCS发病机制中的关键作用，并提示进一步探索检查点免疫疗法用于治疗该疾病。
